RxDoctor Payments Data

Naveed Vehra, MD

Neurology · Glendale, AZNPI 1609889948

Payments from drug & device makers

$15,293in general payments, 2019–2025

Across 814 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • UCB, Inc.$1K
  • Novartis$1K
  • Biogen$924
  • Teva Pharmaceuticals USA, Inc.$891
  • plus $7K from 47 others

What the payments were for

  • Speaking & faculty fees$771%
  • Travel & lodging$6104%
  • Food & beverage$14,60796%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,293 in reported general payments places this provider in the 65th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$251,884
Medicare patients
535
Services billed
2,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab26$228,880
OctagamImmun Globg(Igg)/Malt/Iga Ov5026$161,575
TecfideraDimethyl Fumarate15$138,975
BotoxOnabotulinumtoxina55$88,821
AustedoDeutetrabenazine14$48,064
Nurtec OdtRimegepant Sulfate28$40,760
Dimethyl Fumarate20$40,245
Aimovig AutoinjectorErenumab-Aooe37$39,731
Emgality PenGalcanezumab-Gnlm25$23,028
RytaryCarbidopa/Levodopa14$21,635
Ajovy AutoinjectorFremanezumab-Vfrm24$18,850
QuliptaAtogepant11$11,441
Lacosamide29$7,405
Levetiracetam143$7,051
Memantine Hcl143$4,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$386$202,33554 claims
BiogenTecfidera$924$138,97515 claims
AbbVieBotox, Qulipta$2,204$100,26266 claims
Teva Pharmaceuticals USA, Inc.Austedo$891$48,06414 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$344$23,60332 claims
Upsher-smith Laboratories LLCTopiramate$134$53243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 neurology providers in Arizona.

Other neurology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →